5-iodo-2'-deoxy-2'-fluorouridine | 55612-21-0

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-iodo-2'-deoxy-2'-fluorouridine
• 英文别名: 2'-deoxy-2'-(R)-fluoro-5-iodouridine；5-iodo-2’-fluoro-2’-deoxyuridine；2'-Deoxy-2'-fluoro-5-iodouridine；1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
• CAS: 55612-21-0
• 化学式: C₉H₁₀FIN₂O₅
• 分子量: 372.092
• InChiKey: IPVFGAYTKQKGBM-UAKXSSHOSA-N

物化性质

• 熔点：
  216-218 °C
• 密度：
  2.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 储存条件：
  2-8℃

制备方法与用途

2'-脱氧-2'-氟-5-碘尿苷是一种嘌呤核苷类似物，它具有广泛的抗肿瘤活性，特别针对惰性淋巴系统恶性肿瘤。其抗癌机制主要通过抑制DNA合成和诱导细胞凋亡来实现。

反应信息

• 作为反应物：
  描述：

  5-iodo-2'-deoxy-2'-fluorouridine 在 bis-triphenylphosphine-palladium(II) chloride 、 一氯化碘 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 16.5h， 生成 (E)-5-(2-iodovinyl)-2'-ribofluoro-2'-deoxyuridine
  参考文献：
  名称：

  Synthesis and Cellular Uptake of 2‘-Substituted Analogues of (E)-5-(2-[¹²⁵I]Iodovinyl)-2‘-deoxyuridine in Tumor Cells Transduced with the Herpes Simplex Type-1 Thymidine Kinase Gene. Evaluation as Probes for Monitoring Gene Therapy

  摘要：

  A useful synthetic methodology was developed to synthesize and radiolabel a series of (E)-5-(2-[I-125]iodovinyl)uracil nucleoside substrates for herpes simplex virus type-1 thymidine kinase (HSV-1 TK). (E)-5-(2-[I-125]Iodovinyl)-2'-deoxyuridine ([I-125]IVDU, 10), (E)-5-(2-[I-125]iodovinyl)-2'-fluoro-2'-deoxyuridine ([I-125]IVFRU, 11), (E)-5-(2-[I-125]iodovinyl)-2'-fluoro-2'-deoxyarabinouridine ([I-125]IVFAU, 12), and (E)-5-(2-[I-125]iodovinyl)arabinouridine ([I-125]IVAU, 13) were synthesized in 63-83% radiochemical yield by reaction of the unprotected (E)-5-(2-(trimethylsilyl)vinyl) precursors (6-9) with [I-125]ICl. Cellular uptake of these labeled compounds (10-13) was evaluated in vitro. All compounds showed minimal uptake in the KBALB cell line. However, increased uptake was observed for all compounds in KBALB-STK cells which are transduced with a replication incompetent Moloney murine leukemia virus vector encoding the HSV-1 TK gene. The results indicate that uptake of these compounds in KBALB-STK cells is variable and highly dependent on the nature of the sugar 2'-substituent. When a fluoro (12) or a hydroxy (13) substituent is present in the arabinofuranosyl (up) configuration at the 2'-position, there is diminished cellular uptake in KBALB-STK cells relative to hydrogen (10) or fluorine (11) in the ribofuranosyl (down) configuration at the 2'-position. Our results indicate that radiolabeled IVFRU (11) is most promising for further in vivo studies.

  DOI：

  10.1021/jm9606406
• 作为产物：
  描述：

  2'-氟-2'-脱氧尿苷 在 N-碘代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 以82%的产率得到5-iodo-2'-deoxy-2'-fluorouridine
  参考文献：
  名称：

  与 HIV 抗体 2G12 紧密结合的 2'-氟修饰、RNA 支持的碳水化合物簇的定向进化

  摘要：

  碳水化合物结合蛋白 (CBP) 是医学和生物学中有吸引力的靶标。多价，有几个聚糖与 CBP 中的几个结合口袋结合，对于高亲和力相互作用很重要。在此，我们描述了一种通过定向进化设计多价碳水化合物簇配体的新平台，其中血清稳定的 2'-氟修饰 RNA (F-RNA) 骨架进化以在最佳簇中呈现聚糖。我们通过从约 10 13 的序列库中选择寡甘露糖 (Man 9 ) 聚糖簇验证了该方法，这些簇与具有13 至 36 nM 亲和力的广泛中和 HIV 抗体 2G12 结合。

  DOI：

  10.1021/jacs.1c03194

文献信息

• [EN] COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE SYNTHÈSE DE MOLÉCULES PHOSPHORYLÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2019195494A1

  公开（公告）日：2019-10-10

  The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

  这项发明提供了合成磷酸化有机化合物的组合物和方法，包括核苷三磷酸。
• [EN] NOVEL 6,7-DIHYDROPYRIDO[2,1-A]PHTHALAZIN-2-ONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES 6,7-DIHYDROPYRIDO[2,1-A]PHTALAZIN-2-ONES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017017043A1

  公开（公告）日：2017-02-02

  The invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般式的新化合物：其中R1至R6如本文所述，包括这些化合物的组合物和使用这些化合物的方法。
• [EN] NUCLEIC ACID CHEMICAL MODIFICATIONS<br/>[FR] MODIFICATIONS CHIMIQUES D'ACIDE NUCLÉIQUE
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2010101951A1

  公开（公告）日：2010-09-10

  he present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

  本发明提供了式（1）的核苷和包含至少一种式（2）核苷的寡核苷酸；发明的另一个方面涉及一种抑制细胞中基因表达的方法，该方法包括（a）将本发明的寡核苷酸与细胞接触；和（b）维持步骤（a）中的细胞足够长的时间以获得目标基因mRNA的降解。
• Nucleotide mimics and their prodrugs
  申请人：——

  公开号：US20040059104A1

  公开（公告）日：2004-03-25

  The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

  本发明涉及核苷二磷酸模拟物和核苷三磷酸模拟物，其中包含二磷酸或三磷酸基团模拟物，以及可选的糖修饰和/或碱基修饰。本发明的核苷酸模拟物，以药学上可接受的盐、药学上可接受的前药或药物配方的形式，可用作抗病毒、抗微生物和抗癌剂。本发明提供了一种治疗病毒感染、微生物感染和增生性疾病的方法。本发明还涉及包含本发明化合物的药物组合物，可选地与其他药理活性剂结合。
• Thymidine analogs for imaging
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1916003A1

  公开（公告）日：2008-04-30

  The present invention relates to nucleoside analogues and more particularly to labelled nucleoside analogues of formula (I). It has been found new thymidine analogues can be stably labelled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and I or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.

  本发明涉及核苷类似物，更特别地涉及式(I)的标记核苷类似物。已发现新的胸苷类似物可以稳定地标记具有可检测标记基团。此外，本发明涉及制备上述化合物的方法以及利用这些化合物进行肿瘤细胞的诊断成像和/或治疗增殖性疾病。此外，本发明涉及制备和使用正电子发射化合物进行正电子发射断层扫描（PET）。还公开了一种试剂盒。